-
Sarepta to Resume ELEVIDYS Shipments to Ambulatory Patients After FDA Recommends Removal of Voluntary Hold for Ambulatory Population
The U.S. Food and Drug Administration (FDA) has announced that the agency is now recommending
-
Simply Stated: Updates on Friedreich’s Ataxia (FRDA)
Friedreich’s ataxia (FRDA) is an inherited neuromuscular disease that primarily impacts the nervous system and
-
Del-zota for DMD awarded FDA breakthrough therapy designation
The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to delpacibart zotadirsen, known
-
How art can foster connection in the disability community
Last Sunday, my girlfriend, Amanda, and I co-led an art workshop that brought us both
-
Avidity Biosciences granted Breakthrough Therapy Designation for exon-44 skipping therapeutic, del-zota
CureDuchenne was an early investor in Avidity Biosciences in 2016, and congratulates the company for receiving Breakthrough Therapy
-
FDA Grants Breakthrough Therapy Designation to Avidity’s del-zota
Avidity Biosciences, Inc. today shared that the U.S. Food and Drug Administration (FDA) has granted
-
Sarepta voluntarily halts Elevidys shipments in US after FDA request
Sarepta Therapeutics is voluntarily halting all shipments of Elevidys (delandistrogene moxeparvovec-rokl) in the U.S. after a
-
The importance of advance directives, especially with MD
Amid the hustle and bustle of daily life, many people tend to put off what
-
Update on ELEVIDYS Shipments in the U.S.
This evening, Sarepta Therapeutics issued a press release stating that it has voluntarily and temporarily
-
MDA Ambassador Guest Blog: Parenting, LGMD, and Choosing Joy
Chris Carroll is 41 years old and lives with his wife Joy and two children
